

Dr. Srinivas Murthy
REMAP-CAP ITSC Chair
International Trial Steering Committee REMAP-CAP

November 7, 2024

Dear All,

The REMAP-CAP Data Safety Monitoring Board held a closed session on October 28, 2024 to discuss the latest REMAP-CAP Safety & Efficacy reports.

Dr. Manax led the meeting and a quorum of DSMB members were present.

We reviewed safety data for both the Pandemic Infection Neither Suspected Nor Proven (PINSNP) and Pandemic Infection Suspected or Proven (PISOP) platforms, as well as the overall safety report and Pediatric Safety Report.

Active domains reviewed included

- Antibiotic domain
- Macrolide duration domain
- Corticosteroid domain*
- Influenza antiviral domain*
- Mechanical ventilation acute respiratory failure domain
- COVID-19 Immunoglobulin therapy II domain
- Endothelial modulation domain

Domains with * were discussed in both adult and pediatric populations.

We have no safety concerns at this time.


Reviewing the efficacy report, no platform triggers were achieved at this update. Therefore, the DSMB has no platform decisions to recommend at this time.

The DSMB will continue to monitor safely monthly and looks forward to the next efficacy update.

Your Sincerely,



Victoria G. Manax, MD
Chair REMAP-CAP DSMB



Jason Connor, PhD
Co-chair REMAP-CAP DSMB

cc DSMB members, REMAP-CAP lead investigators, REMAP-CAP trial management, REMAP-CAP SAC, REMAP-CAP ITSC